

# Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative

Raf Bisschops<sup>1</sup>, Miguel Areia<sup>2,3</sup>, Emmanuel Coron<sup>4</sup>, Daniela Dobru<sup>5</sup>, Bernd Kaskas<sup>6</sup>, Roman Kuvaev<sup>7</sup>, Oliver Pech<sup>8</sup>, Krish Ragunath<sup>9</sup>, Bas Weusten<sup>10</sup>, Pietro Familiari<sup>11</sup>, Dirk Domagk<sup>12</sup>, Roland Valori<sup>13</sup>, Michal F Kaminski<sup>14,15</sup>, Cristiano Spada<sup>11</sup>, Michael Bretthauer<sup>14,16</sup>, Cathy Bennett<sup>17</sup>, Carlo Senore<sup>18</sup>, Mário Dinis-Ribeiro<sup>3,19</sup> and Matthew D Rutter<sup>20,21</sup>

United European Gastroenterology Journal  
2016, Vol. 4(5) 629–656

This article is published simultaneously in the journals Endoscopy and the United European Gastroenterology Journal.

Copyright 2016 © Georg Thieme Verlag KG and © by the United European Gastroenterology

Reprints and permissions:  
sagepub.co.uk/journalsPermissions.nav

DOI: 10.1177/2050640616664843

ueg.sagepub.com



## Keywords

Gastroscopy, performance measures, quality indicators, quality, patient safety

Received: 21 July 2016; accepted: 22 July 2016

## Introduction

The European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology (UEG) have identified quality of endoscopy as a major priority and we described our rationale for this

in a first manuscript that also addressed the methodology of the quality initiative process.<sup>1</sup>

The identification of upper gastrointestinal (UGI) performance measures presents a considerable challenge, in contrast to the situation with colonoscopy for instance, where several performance measures

<sup>1</sup>Department of Gastroenterology and Hepatology, University Hospital Leuven, Leuven, Belgium

<sup>2</sup>Gastroenterology Department, Portuguese Oncology Institute, Coimbra, Portugal

<sup>3</sup>Center for Health Technology and Services Research (CINTESIS), University of Porto, Porto, Portugal

<sup>4</sup>Institut des Maladies de l'Appareil Digestif, CHU de Nantes, Nantes, France

<sup>5</sup>Gastroenterology Department, University of Medicine and Pharmacy, Targu Mures, Romania

<sup>6</sup>Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

<sup>7</sup>Endoscopy, Yaroslavl Regional Cancer Hospital, Yaroslavl, Russian Federation

<sup>8</sup>Klinik für Gastroenterologie und interventionelle Endoskopie, Barmherzige Brüder Regensburg, Regensburg, Germany

<sup>9</sup>NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus, Nottingham, UK

<sup>10</sup>Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, The Netherlands

<sup>11</sup>Digestive Endoscopy Unit, Agostino Gemelli University Hospital, Rome, Italy

<sup>12</sup>Department of Internal Medicine, Joseph's Hospital, Warendorf, Germany

<sup>13</sup>Department of Gastroenterology, Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UK

<sup>14</sup>Department of Health Management and Health Economy and KG Jebsen Centre for Colorectal Cancer, University of Oslo, Oslo, Norway

<sup>15</sup>Department of Gastroenterological Oncology, The Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, and Medical Center for Postgraduate Education, Warsaw, Poland

<sup>16</sup>Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway

<sup>17</sup>Centre for Technology Enabled Research, Coventry University, Coventry, UK

<sup>18</sup>CPO Piemonte, AOU Città della Salute e della Scienza, Torino, Italy

<sup>19</sup>Servicio de Gastroenterologia, Instituto Portugues de Oncologia Francisco Gentil, Porto, Portugal

<sup>20</sup>Department of Gastroenterology, University Hospital of North Tees, Stockton-on-Tees, UK

<sup>21</sup>School of Medicine, Durham University, Durham, UK

## Corresponding author:

Raf Bisschops, Department of Gastroenterology and Hepatology, University Hospital Leuven, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.  
Email: raf.bisschops@uzleuven.be

(inspection time, adenoma detection rate, and interval cancers, among others) have been identified over the last decade.<sup>2,3</sup> Following the Quality in UGI Endoscopy meeting held in Lisbon in 2013, it was clear that there was a need to identify performance measures for the UGI tract, and that quality standards could be identified although there is a paucity of evidence. This lack of evidence helps however to identify research priorities for the development of clinical trials that will further validate and substantiate the implementation of performance measures.

The aim therefore of the UGI working group was twofold: (a) to identify performance measures for UGI endoscopy; (b) to identify the evidence or absence of evidence that would develop the research priorities in this field.

We used an innovative methodology to facilitate the quality initiative process, which combined a thorough search and standardized evaluation of the available evidence for each clinical question, followed by a Delphi process (<http://is.njit.edu/pubs/delphibook/delphibook.pdf>) using an online platform.<sup>4,5</sup> This online platform permitted iterative rounds of modification and comment by all members of the UGI working group until agreement was reached on the performance measure. We now report these newly identified performance measures.

## Methodology

We previously described the multistep process for the methodology to develop performance measures.<sup>1</sup> Briefly, following the Lisbon meeting in 2013, a list of 56 possible performance measures was distributed to all of the working group members for comments, suggestions, and shortcomings in September 2014. Every participant was required to comment on all of the proposed performance measures during teleconferences that took place between 1 October–18 December 2014.

All possible performance measures that were identified by this process were structured using the PICO framework (where P stands for population/patient; I for intervention/indicator; C for comparator/control; and O for outcome) to inform searches for available evidence to support the performance measures. This process resulted in 67 possible performance measures and 108 PICOs.

Due to the timeframe for this first initiative and the wide range of pathology in the UGI tract, the working group had to prioritize general UGI endoscopy topics within the abundance of proposed performance measures and PICOs. As part of this prioritization, PICOs that were concerned with areas where guidelines were already available or under development were omitted.

We also excluded PICOs that focused on: the assessment of effectiveness, or comparative effectiveness, of specific treatments (e.g. administration of proton pump inhibitors (PPIs) before endoscopy for acute bleeding, percentage of patients undergoing endoscopic resection in Barrett's esophagus with high grade dysplasia (HGD) before ablation); legal or local regulation (informed consent); histopathology (e.g. the need for confirmation/revision of a diagnosis of dysplasia by an independent pathologist); and service working group issues (e.g. adequate management of anticoagulants, sedation, etc.).

The initial priority list was developed during a face-to-face meeting on 14 February 2015. In total, 44 PICOs were retained as the basis for literature searches. Several disease-specific performance measures were also developed (Barrett's esophagus, intestinal metaplasia in the stomach, and squamous cell cancer (SCC) in the esophagus).

The PICOs, and the clinical statements derived from these which were organized into eight domains on the basis of their clinical applications, were adapted and/or excluded during the iterative rounds of comments and suggestions from the working group members during the Delphi process. The evolution and adaptation of the different PICOs and clinical statements during the Delphi process can be reviewed in the Supplementary Material. In total, working group members participated in four rounds of voting to agree on the performance measures in predefined domains and their respective thresholds, which are discussed below. The agreement that is given for the different statements refers to the last voting round in the Delphi process. A statement was accepted if at least 80% agreement was reached after a minimum of two voting rounds.

The performance measures are displayed in boxes under the relevant domain. Each box describes the performance measure and the rationale behind its adoption, the agreement on acceptance during the modified Delphi process, and the grading of the available evidence, along with details of how the score should be measured and the desired threshold.

During the Delphi process, the Quality Improvement Committee (QIC) chairs distinguished key performance measures from minor performance measures to assist service providers with decisions about the implementation of performance measures in their endoscopy services. Reasons to qualify a performance measure as minor included the measure being very disease specific (e.g. detection of neoplasia during surveillance of Barrett's esophagus or gastric intestinal metaplasia) or that its implementation might be relatively difficult and dependent on the availability of

adequate software for auditing of the performance measures. The division and allocation of performance measures to key and minor performance measures was agreed by the UGI working group in an additional face-to-face meeting in April 2016.

The number of cases that need to be audited to adequately assess if the threshold for a certain performance measure is reached can be calculated by estimating the 95% confidence intervals (CIs) for a predefined threshold and variable sample size (see Appendix 1). For reasons of practicality and feasibility when implementing an audit, the working group agreed that 100 procedures (or all, if <100 procedures had been performed) should be measured to assess the performance measure. Ideally this should be done at an individual procedure level but, as this requires robust and sophisticated software, we suggest that the assessment is first performed at a service level. If problems are detected at a service level, further analysis at an individual level is then required to identify possible targets for improvement.

### Performance measures for UGI endoscopy

In the first round of development, the working group accepted 11 performance measures in total, after a total of four voting rounds in the modified Delphi process. The evidence quality (assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria)<sup>6</sup> for most of these performance measures is low; however, this does not indicate that a performance measure is not important.

Taking into account both the feasibility of implementation and the possible impact on diagnostic quality and patient outcome, we identified six key and five minor performance measures (Figure 1 and Table 1). Nevertheless, all the performance measures were deemed valuable by the working group members and were obtained after a rigorous process, as described above. From a practical viewpoint, it may be desirable to implement the key performance measures first in those units that are not presently monitoring any performance measures. Once a culture of quality measurement is accepted and software is available, the minor performance measures may then further aid monitoring of the quality of UGI endoscopy.

All of the performance measures are described below, according to the domain to which they are attributed. The PICO and statements that were used during the modified Delphi process to develop the performance measures can be found in the Supplementary Material. The statement numbers correspond to those used in Supplementary Material.

### Domain: pre-procedure

The acceptance of this performance measure (Box 1) is based on agreement with the following statements:


- Patients referred for scheduled UGI endoscopy should be fasting (statement number N1.1 (see Supplementary Material)) Agreement: 100%.
- Patients referred for UGI endoscopy should be fasting for solids for at least six hours prior to the procedure. (N1.2) Agreement: 91%.
- Patients referred for UGI endoscopy are allowed to take in water until two hours prior to the procedure. (N1.3) Agreement: 100%.

Two studies were found that addressed these instructions and the duration of fasting prior to a scheduled UGI endoscopy.<sup>7,8</sup> In both studies, the authors mainly assessed the fasting time for liquids. The fasting time for solids was at least six hours prior to the endoscopy in both studies, with a good effect on visibility during endoscopy.

In the study by Koeppel et al.,<sup>7</sup> general discomfort was reported less frequently by patients who had a drink of water (200 ml) two hours before the procedure than in those who were fasting for solids and liquids for a full eight hours (18% vs 42%;  $p=0.010$ ). Even though the endoscopists subjectively observed more liquid in the stomach of the former group, no cases of aspiration were observed in the sample of 50 lightly sedated patients.

De Silva et al.<sup>8</sup> also reported lower discomfort scores when water ad libitum was allowed until one hour before the procedure (recorded volumes drunk were 200–410 ml) compared with no water being allowed during a six-hour pre-endoscopy fast (5.6 vs 9.7;  $p<0.0001$ ). No significant differences were found for complications and safety outcomes, apart from a significant difference in the volume of retained fluid in the gastric fundus, this being greater when water was drunk until one hour prior to the procedure, which was performed without sedation. Again no cases of aspiration were observed.

The outcome “incomplete examination” was not reported in the retrieved studies. The outcome “good or normal visibility of gastric mucosa” could be used as an indirect outcome for the evaluation of incomplete examination. This outcome was consistently high after both two hours/one hour minimum of no fluids and nil by mouth for at least six hours (96% vs 98%<sup>7</sup> and 93% vs 100%,<sup>8</sup> respectively).



**Figure 1.** The domains and performance measures chosen by the working group. MAPS: management of precancerous conditions and lesions in the stomach; SCC: squamous cell carcinoma.

**Table 1.** Description of the different performance measures.

Key performance measures	Minor performance measures
Fasting instructions prior to UGI endoscopy	Minimum 7-minute procedure time for first diagnostic UGI endoscopy and follow-up of gastric intestinal metaplasia
Documentation of procedure duration	Minimum 1-minute inspection time per cm circumferential Barrett's epithelium
Accurate photodocumentation of anatomical landmarks and abnormal findings	Use of Lugol chromoendoscopy in patients with a curatively treated ENT or lung cancer to exclude a second primary esophageal cancer
Accurate application of standardized disease-related terminology	Application of validated biopsy protocol to detect gastric intestinal metaplasia (MAPS guidelines)
Application of Seattle protocol in Barrett's surveillance	Prospective registration of Barrett's patients
Accurate registration of complications after therapeutic UGI endoscopy	

UGI, upper gastrointestinal; ENT, ear, nose, and throat; MAPS, management of patients with precancerous conditions and lesions of the stomach.

Although no data from the two available studies directly assessed the duration of fasting for solids, it appears that an interval of at least six hours is safe and effective for UGI endoscopy in patients without any history or predisposing factors for delayed gastric emptying. For endoscopies that are planned to be performed in the afternoon, patient satisfaction may be increased if a small breakfast is allowed.

Unlike with colonoscopy, we do not have a standardized scale to measure “gastric preparation” for UGI endoscopy. We advise that the contents of the stomach, such as food residues, blood, bile, or the presence of

bubbles, should be reported, along with information on whether a waterjet system was used to improve mucosal visualization. Just recording this as a surrogate performance measure may however omit patients that are sent home again because they did not receive fasting instructions. Recording that proper instructions were given should therefore be done prior to the endoscopy itself and this could be included in the pre-assessment part of the endoscopy report (together with, for instance, the informed consent). This would mean that patients who show up for endoscopy having not received proper instructions and therefore have their

**Box 1.** Pre-procedure.

Key performance measure	Fasting instructions
Description	Percentage of patients receiving proper instructions for fasting prior to UGI endoscopy
Domain	Pre-procedure
Category	Process
Rationale	Patient safety and comfort Efficacy of UGI endoscopy
Construct	<b>Denominator:</b> patients undergoing a UGI endoscopy ( <b>note:</b> patients whose endoscopies are postponed because of lack of proper instructions should also be included in the calculation of the denominator) <b>Numerator:</b> patients in the denominator who received proper instructions for fasting (two hours for liquids and six hours for solids), as reported in the pre-assessment part of the endoscopy report <b>Exclusions:</b> emergency endoscopies Calculation: proportion (%) Level of analysis: service level Frequency: yearly for a sample of 100 consecutive UGI endoscopies on a service level
Standards	Minimum standard: 95% Target standard: 95% If the minimum standard is not reached, information channels to patients and healthcare providers should be reviewed and revised on a service level After evaluation and adjustment, close monitoring should be performed with a further audit within six months
Consensus agreement for performance measure	91%
PICO number (see Appendix 2)	1
Evidence grading	Very low quality

endoscopy cancelled should be included in any audits of this performance measure.

### *Domain: completeness of procedure*

The acceptance of this performance measure (Box 2) is based on agreement with the following statements:

- A UGI endoscopy in a patient who has not undergone a previous gastroscopy within the last three years should include inspection of the esophagus, stomach, and duodenum, and should last for at least seven minutes from intubation to extubation. (N2.2) Agreement: 80%.
- Although the evidence to support this is of very low quality, the major duodenal papilla should be visualized and photographed in all UGI endoscopies in patients with normal anatomy when a full examination is intended. (N2.1) Agreement: 73%.

In contrast to colonoscopy, there is a paucity of data on the assessment of a complete procedure. As a definition, “reaching the duodenum” seems too trivial: it does not really reflect endoscopic competence as it is

easy to achieve; there is no data comparable to cecal intubation rate in the colon that supports its relationship to better disease detection.

During the discussions of the working group, there was a strong emphasis on trying to define this performance measure and searching the literature for an anatomical landmark or finding that might be related to disease detection. We formulated several PICOs to assess whether reaching any specific anatomical landmark yielded a better rate of diagnosis. One may speculate whether documentation that the major papilla has been visualized can serve as an auditable performance measure for completeness of the procedure in a patient referred for a complete UGI endoscopy. Analogous to cecal intubation, it cannot be achieved in all endoscopies and is less trivial than reaching the second portion of the duodenum. In the absence however of any data to support this, no consensus was reached on this statement (only 73% agreement) and the working group therefore formulated this as one of the research priorities (Table 2).

We did however find one study that aimed to evaluate whether the length of time spent on UGI endoscopy improved the diagnostic yield. This was a retrospective cohort study by Teh et al.<sup>9</sup> that aimed to determine the

**Box 2.** Completeness of procedure.

Key performance measure	Documentation of procedure duration
Description	Percentage of endoscopy reports that record the duration of the procedure from intubation to extubation
Domain	Completeness of procedure
Category	Process
Rationale	Completeness of UGI endoscopy cannot be defined only by the duodenum having been reached A longer inspection time reflects a more complete examination and is related to higher diagnostic yield during UGI endoscopy
Construct	Record the time from intubation to extubation of the endoscope <b>Denominator:</b> all UGI endoscopies <b>Numerator:</b> procedures in the denominator that report the time of the procedure from intubation to extubation <b>Exclusions:</b> none Calculation: proportion (%) Level of analysis: service and, if necessary, individual level Frequency: yearly for a sample of 100 consecutive UGI endoscopies. If the minimum standard is not reached, analysis on an individual level should be performed
Standards	Minimum standard: 90% Target standard: 90% Recording the duration of an examination should be attempted and should mostly be possible If the threshold is not reached on a service level, the service should assess whether technical support is sufficient to accurately record the procedure time If the threshold is not reached for an individual endoscopist, feedback should be provided, followed by close monitoring for three months to assess the performance of the individual endoscopist After evaluation and adjustment, close monitoring should be performed with a further audit within 6 months
Consensus agreement for performance measure	82%
PICO numbers (see Appendix 2)	2, 3
Evidence grading	Very low quality

diagnostic yield for early neoplastic lesions in the stomach. The study included 837 symptomatic patients with no history of gastric cancer who underwent a first diagnostic endoscopy by one of 16 endoscopists. The mean examination time for the 224 examinations without any abnormal findings or biopsies taken was 6.6 min, which allowed the definition of a cut-off time of  $\geq 7$  min to distinguish between “slow” versus “fast” procedures. Afterwards, in a retrospective evaluation of the 837 endoscopies, they concluded that a “slow” endoscopist (who took on average at least seven minutes to perform a normal endoscopy) was twice as likely to detect high risk gastric lesions, defined as biopsy evidence of intestinal metaplasia, gastric atrophy, gastric dysplasia, or cancer (odds ratio (OR) 2.50, 95% CI 1.52–4.12) and three times as likely to detect a case of dysplasia or cancer (OR 3.42, 95% CI 1.25–10.38) than a “fast” endoscopist (who took fewer than seven minutes on average).

A similar concept of measuring length of time for inspection, but in the specific context of Barrett’s

esophagus, has shown increased detection of dysplasia with an inspection time of one minute per cm of Barrett’s esophagus.<sup>10</sup>

Only one study has evaluated the correlation between increased detection of gastric dysplasia or gastric cancer and other UGI endoscopic diagnoses.<sup>11</sup> Park et al. retrospectively analyzed 54,889 records of patients who underwent a screening UGI endoscopy, performed by 66 experienced endoscopists, from 2006–2013 in a single center in Korea. Any diagnoses of reflux esophagitis, Barrett’s esophagus, atrophic gastritis, intestinal metaplasia, erosion, ulceration, polyps, subepithelial lesions, xanthoma, angiodysplasia, or a diverticulum were recorded and the relevant records were re-evaluated with respect to increased detection of early gastric neoplasia. In multivariate analysis, the detection rates of gastric subepithelial lesions and gastric diverticula were independently associated with the detection rate of early gastric neoplasms.

The acceptance of this performance measure (Box 3) is based on agreement with the following statements:

**Table 2.** Research priorities identified by the working group.

<p>What is the percentage detection of dysplasia in a Barrett's surveillance program in a general endoscopy practice?</p> <p>What is the percentage of intestinal metaplasia in the stomach throughout Europe in a general endoscopy practice?</p> <p>Could visualization of the papilla of Vater be used as a measure for a complete and high quality endoscopy?</p> <p>Does the percentage of endoscopies where the papilla is visualized correlate with a higher general diagnostic yield during UGI endoscopy?</p> <p>What is the relationship between inspection time during UGI endoscopy and diagnostic yield?</p> <p><b>The role of endoscopy in redefining diseases of the UGI tract</b></p> <p>Endoscopy with or without biopsies</p> <p>Do biopsies alter the management of patients with Barrett's esophagus or eosinophilic esophagitis?</p> <p>What is the role of advanced imaging in a general endoscopy practice for dysplasia detection in:</p> <p>Barrett's esophagus</p> <p>Squamous cancer detection in high risk patients</p> <p>Intestinal metaplasia in the stomach?</p> <p>Can automated image analysis remove the need for biopsies and guide the management of patients with:</p> <p>Barrett's esophagus</p> <p>Intestinal metaplasia of the stomach</p> <p>Celiac disease?</p> <p>What is the role of teaching modules in training endoscopists in image interpretation and lesion recognition?</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

UGI, upper gastrointestinal.

- High quality reporting includes photodocumentation of all normal anatomical landmarks and abnormal findings. (N3.1) Agreement: 100%.
- An accurate endoscopy report for reflux disease includes documentation of the anatomical hallmarks (diaphragm indentation, top of gastric folds). (N4.1) Agreement: 100%.
- An accurate endoscopy report for reflux disease includes application of the Los Angeles classification (N4.2). Agreement: 100%.
- An accurate endoscopy report for Barrett's esophagus includes documentation of the anatomical landmarks (diaphragm indentation, top of gastric folds). (N4.3) Agreement: 100%.
- The Prague criteria should be used to report the results of endoscopic examination of Barrett's esophagus. (N4.4) Agreement: 100%.

No data exist to support the view that photodocumentation of all normal anatomical landmarks and abnormal findings will improve diagnostic yield. However, photodocumentation should be considered a general quality improvement in comparison with previous reports that were made before dedicated reporting software was available. Most endoscopic systems now enable digital picture acquisition, therefore the working group strongly agreed on the inclusion of digital photography in reports. This measure is supported by endoscopic societies and experts suggest it might be an indirect quality indicator for careful inspection of the digestive lumen.<sup>12-14</sup>

The minimum number of pictures to be collected, combining relevance and applicability, in a normal endoscopic examination should be 10, namely: proximal esophagus, distal esophagus, Z line and diaphragm indentation, cardia and fundus in inversion,

corpus in forward view including lesser curvature, corpus in retroflex view including greater curvature, angulus in partial inversion, antrum, duodenal bulb, and second part of duodenum. The working group suggested that it may be desirable to document more extensively in specific surveillance examinations, such as for Barrett's esophagus (e.g. one picture per cm of Barrett's esophagus),<sup>10</sup> or where there are extensive gastric premalignant conditions (e.g. 21 pictures of the stomach).<sup>13</sup>

In addition, several validated classifications have been developed for specific pathologies. The working group agreed that the use of these classifications in conjunction with photodocumentation improves comparability and accurate information exchange among gastroenterologists, both in the clinical setting and for investigational purposes. In the UGI tract, this is especially true for the Los Angeles classification for the reporting of reflux esophagitis and the Prague classification for Barrett's esophagus.<sup>15-18</sup>

Implementation of this performance measure is inevitably dependent on the availability of image acquisition and software to incorporate images into the report. Because this performance measure simplifies and improves communication between different endoscopists, implementation of appropriate software should be prioritized by hospital policy makers. The working group recognizes that gastroenterologists performing procedures mainly in their own surgeries will often struggle to find a reasonable way to be reimbursed for the considerable cost of this software.

### *Domain: identification of pathology*

The acceptance of this performance measure (Box 4) is based on agreement with the following statements:

**Box 3.** Accurate photodocumentation.

Key performance measure	Accurate photodocumentation
Description	Percentage of endoscopy reports with accurate photodocumentation of anatomical landmarks and all abnormal findings
Domain	Completeness of procedure
Category	Process
Rationale	Photodocumentation of all anatomical landmarks is an indicator of a complete examination Accurate photodocumentation of abnormal findings allows for better communication and follow-up
Construct	Accurate photodocumentation includes at least one representative picture of each of the following anatomical landmarks: duodenum, major papilla, antrum, angulus, corpus, retroflex of the fundus, diaphragmatic indentation, upper end of the gastric folds, squamocolumnar junction, distal and proximal esophagus (i.e. at least 10 images in total) There should be pictures of all abnormal findings mentioned in the report <b>Denominator:</b> all diagnostic UGI endoscopies <b>Numerator:</b> procedures in the denominator that contain accurate photodocumentation, as detailed above <b>Exclusions:</b> <ul style="list-style-type: none"> <li>- Therapeutic procedures</li> <li>- Follow-up endoscopies performed within 12 months of a previous endoscopy and for a previously diagnosed disease or condition (coeliac disease, varices, ulcers, cancer after any treatment, dysplastic Barrett's esophagus, gastric dysplasia, duodenal polyps, infections, inflammation, bleeding, or endoscopic treatment of any of the aforementioned)</li> <li>- Emergency endoscopy</li> <li>- Endoscopy with a specific diagnostic purpose without the need for a full evaluation: evaluation of a fistula or perforation</li> <li>- Early termination of endoscopy due to patient intolerance or for reasons of safety</li> </ul> Calculation: proportion (%) Level of analysis: service and, if necessary, individual level Frequency: yearly for a sample of 100 consecutive UGI endoscopies. If the minimum standard is not reached, analysis on an individual level should be performed
Standards	Minimum standard: 90% Target standard: 90% If the threshold is not reached on a service level, the service should assess whether technical support is sufficient for image acquisition and integration into the report If the threshold is not reached for an individual endoscopist, feedback should be provided, followed by close monitoring for three months to assess the performance of the individual endoscopist After evaluation and adjustment, close monitoring should be performed with a further audit within six months Factors such as whether the examination is diagnostic or therapeutic should be recorded to allow subgroup analysis and future adaptation of the performance measure
Consensus agreement for performance measure	91%
PICO numbers (see Appendix 2)	4, 5
Evidence grading	Very low quality

- The entire procedure for surveillance of intestinal metaplasia should last at least seven minutes from scope intubation to scope extubation of the patient. (N6.1). Agreement: 100%.
- A UGI endoscopy in a patient who has not undergone a previous gastroscopy within the last three years should include inspection of the esophagus, stomach, and duodenum, and should last for at least seven minutes from intubation to extubation. (N2.2) Agreement: 80%.

The evidence for this performance measure is mainly derived from the study by Teh et al.<sup>8</sup> By using a cut-off time of  $\geq 7$  min per endoscopy, from intubation to extubation, endoscopists performing above the cut-off (i.e. longer inspection times) detect two times as many high risk gastric lesions (intestinal metaplasia, gastric atrophy, gastric dysplasia, or cancer) and three times as many dysplastic lesions and gastric cancers. The study did not evaluate

**Box 4.** Inspection time in the stomach.

Minor performance measure	Inspection time in the stomach
Description	Percentage of first-time gastroscopies and follow-up gastroscopies for gastric intestinal metaplasia lasting more than seven minutes from intubation to extubation
Domain	Identification of pathology
Category	Process
Rationale	Longer inspection times allow the detection of more lesions in the stomach
Construct	Record time from intubation to extubation of the endoscope <b>Denominator:</b> first-time diagnostic UGI endoscopies or follow-up gastroscopies for gastric intestinal metaplasia <b>Numerator:</b> procedures in the denominator with the duration of the procedure documented as being at least seven minutes from intubation to extubation ( <b>note:</b> procedures without a recorded time should be regarded as fails) <b>Exclusions:</b> - Therapeutic procedures - Follow-up endoscopy within 36 months of a previous endoscopy for follow-up of gastric intestinal metaplasia - Emergency endoscopy - Endoscopy with a very specific diagnostic focus where there is no intent to detect stomach pathology: e.g. evaluation of a fistula, perforation - Early termination of endoscopy due to patient intolerance or for reasons of safety Calculation: proportion (%) Level of analysis: service and, if necessary, individual level Frequency: yearly for a sample of 100 consecutive UGI endoscopies. If the minimum standard is not reached, analysis on an individual level should be performed
Standards	Minimum standard: 90% Target standard: 90% Recording the duration of an examination should be attempted and should mostly be possible If the threshold is not reached on a service level, the service should assess whether technical support is sufficient to accurately record the procedure time If the threshold is not reached for an individual endoscopist, feedback should be provided, followed by close monitoring for three months to assess the performance of the individual endoscopist After evaluation and adjustment, close monitoring should be performed with a further audit within six months
Consensus agreement for performance measure	82%
PICO number (see Appendix 2)	1
Evidence grading	Very low quality evidence

differing diagnostic yields in the esophagus or duodenum between endoscopists but it provides evidence for the stomach that is comparable to that for inspection times in the colon.<sup>18</sup>

The interval of three years in the statement from the Delphi process stems from the suggestion of the European consensus on “Management of precancerous conditions and lesions in the stomach (MAPS)” guideline.<sup>19,20</sup> The three-year interval was suggested among experts to be the best clinically applicable interval for endoscopic surveillance of extensive atrophy and/or extensive intestinal metaplasia. This three-year interval strategy has been shown more recently, in a European population between 50–75

years of age, to be cost-effective as a surveillance strategy.<sup>21</sup>

The acceptance of this performance measure (Box 5) is based on agreement with the following statements:

- Abnormal findings should be reported according to available internationally validated and standardized terminology. (N3.2) Agreement: 100%.
- An accurate endoscopy report for reflux disease includes application of the Los Angeles classification. (N4.2) Agreement: 100%.
- The Prague criteria should be used to report the results of endoscopic examination of Barrett’s esophagus. (N4.4) Agreement: 100%.

**Box 5.** Use of standardized terminology.

Key performance measure	Use of standardized terminology
Description	Percentage of endoscopy reports with accurate application of standardized disease-related terminology
Domain	Identification of pathology
Category	Process
Rationale	Uniformity in communication
Construct	<p>Record the use of the:</p> <ul style="list-style-type: none"> <li>- Los Angeles classification for erosive esophagitis</li> <li>- Zargar classification for caustic esophagitis</li> <li>- Prague classification for Barrett's esophagus</li> <li>- Forrest classification for bleeding ulcers</li> <li>- Spigelman classification for duodenal adenomas in patients with familial adenomatous polyposis (FAP)</li> <li>- Paris classification for visible lesions in the stomach and esophagus</li> <li>- Baveno classification for varices</li> </ul> <p><b>Denominator:</b> all endoscopy reports addressing one or more of the aforementioned group of pathologies</p> <p><b>Numerator:</b> reports with appropriate use of all disease-related terminology</p> <p>The performance measure is only met when all applicable disease-related terminology is used in a report, so for instance in a patient with esophagitis and Barrett's esophagus both the Los Angeles and Prague classifications should be used</p> <p><b>Exclusions:</b> none, but limited to the specified diseases</p> <p>Calculation: proportion (%)</p> <p>Level of analysis: service and, if necessary, individual level</p> <p>Frequency: yearly for a sample of 100 consecutive UGI endoscopies. If the minimum standard is not reached, analysis on an individual level should be performed</p>
Standards	<p>Minimum standard: 95%</p> <p>Target standard: 95%</p> <p>Recording of the final diagnosis of the endoscopy is fundamental to allow the calculation of this performance measure and therefore its implementation may be more difficult</p> <p>If the threshold is not reached at a service level, the service should assess whether technical support is sufficient to make a search for auditable endoscopies feasible, based on software that allows the diagnosis on an endoscopy report to be searched</p> <p>If the threshold is not reached for an individual endoscopist, feedback should be provided, followed by close monitoring for 6 months to assess the performance of the individual endoscopist</p> <p>After evaluation and adjustment, close monitoring should be performed with a further audit within 6 months</p>
Consensus agreement for performance measure	91%
PICO numbers (see Appendix 2)	6-13
Evidence grading	Very low quality

The quality of endoscopy is closely related to the quality of the report and the use of standardized terminology enables better communication between endoscopists and unequivocal discrimination of disease-related findings.

The working group considered accurate reporting as one of the main topics for quality assurance. Besides reporting and documentation of anatomical landmarks, the correct use of available and validated terminology for specific diseases was considered to be

a cardinal point for quality improvement. It enables the gathering of sound epidemiological data and is a prerequisite for auditing the quality of endoscopic reports. Although the literature searches for the PICOs did not render any evidence in terms of higher diagnostic yield or proven efficacy for better physician interaction and communication, the statements on implementing standardized terminology as a quality measure for accurate reporting all reached 100% agreement.

The Paris classification is a uniform and relatively well established endoscopic classification for early neoplastic lesions,<sup>22,23</sup> with clinical value in terms of the prediction of the risk of submucosal invasion and therefore eligibility for endoscopic treatment;<sup>23</sup> however, little is known about the interobserver agreement of this classification. Recently, the value of this classification system has been questioned in an interobserver study for polyp assessment in the colon, which showed a Kappa value of 0.42 and a mean pairwise agreement of 67%.<sup>24</sup> This study indicates that further research is clearly necessary to assess the applicability of the Paris classification or perhaps to simplify it.

The Los Angeles classification for erosive reflux disease was validated when it was introduced in 1996<sup>25</sup> and demonstrated that interobserver agreement for the assessment of minimal changes, mucosal breaks, demarcated areas of slough or erythema, and complications was good. Because of the availability of interobserver data and the fact that this classification is now used most widely, the working group opted to implement the Los Angeles classification as the standard for endoscopic assessment of reflux disease.<sup>25,26</sup>

Similarly, the Prague classification is a relatively straightforward and reproducible score, which enables better communication between endoscopists. The score has been validated among experts<sup>18</sup> and in two additional studies among trainees and community-based endoscopists, strengthening the value of the Prague classification for the accurate description of Barrett's esophagus and the length of the hiatal hernia.<sup>27,28</sup>

The ESGE guideline on the diagnosis and management of nonvariceal UGI bleeding has strongly recommended the uniform use of the Forrest classification, as used in several studies assessing the risk for peptic ulcer bleeding and rebleeding.<sup>29,30</sup> Therefore it is clinically important that this classification is used in the endoscopy report in order to ascertain the correct clinical management after endoscopy for UGI bleeds.<sup>31</sup>

Other classification systems that should be implemented are Zargar's classification for caustic esophagitis,<sup>32</sup> the Baveno classification for grading of esophageal varices,<sup>33,34</sup> and Spigelman's classification for duodenal polyps in FAP syndrome.<sup>35,36</sup> Although there is less data available in terms of reproducibility, these scoring systems are relatively simple to apply and have an intrinsic clinical value in terms of patient management and follow-up.

The working group accepted that although agreement was reached about the use of the aforementioned standardized terminology in the modified Delphi process, its implementation may be not so easy. In particular, in order to provide data that will enable this performance measure to be audited, there is a requirement for an adequate electronic reporting system that

can match a diagnosis (e.g. bleeding duodenal ulcer) to the standardized terminology being used (Forrest classification). A prerequisite of such a reporting system is that it would permit automated queries to be run at regular intervals and feedback to be supplied to individual endoscopists. Outputs from such reporting systems can help to improve the performance for this measure: for instance, the system can be adapted to provide a reminder of the criteria of the relevant classification system and so that a report cannot be validated unless, when a particular diagnosis has been made, the corresponding terminology is used. If such a system is in place, systematic electronic reports are encouraged and the over-riding of this requirement by the endoscopist should be discouraged.

The acceptance of this performance measure (Box 6) is based on agreement with the following statement:

- Inspection time in the esophagus for surveillance of a Barrett's segment should be at least 1 min/cm of circumferential extent of Barrett's epithelium. (N4.5) Agreement: 90%.

No studies were found that have directly addressed the comparison between measuring or not measuring the inspection time. One study aiming to determine whether the inspection time in Barrett's esophagus correlated with the detection of endoscopically suspicious lesions and/or Barrett's esophagus-associated neoplasia, namely HGD or early adenocarcinoma (EAC), was considered partially relevant.<sup>10</sup> It was a cross-sectional post hoc analysis of data from a multicenter, prospective clinical trial of 112 patients that investigated the performance of novel imaging techniques for dysplasia detection during Barrett's esophagus surveillance. The study found that greater proportions of patients had an endoscopically suspicious lesion with increasing inspection times ( $\leq 2$  min, 30%; 3–4 min, 35.5%; 5–6 min, 82.1%;  $\geq 7$  min, 84.6%;  $p < 0.001$ ) and a greater proportion were found to have HGD/EAC ( $\leq 2$  min, 15%; 3–4 min, 32.3%; 5–6 min, 46.4%;  $\geq 7$  min, 69.2%;  $p = 0.001$ ). The study suggested that an inspection time of 1 min/cm of Barrett's esophagus resulted in increased detection of neoplasia.

Although this study had certain limitations and did not reflect the real-life prevalence of Barrett's esophagus dysplasia in a community-based hospital, the working group members agreed to support this performance measure with a high degree of agreement. In contrast to the detection of colon polyps, where a solid scientific basis seems to exist with regard to the measurement of inspection time during withdrawal<sup>3,19</sup> as a performance measure, for UGI endoscopy there is a paucity of scientific data.<sup>9,10</sup> Nonetheless, it seems reasonable to

**Box 6.** Inspection time of Barrett's esophagus.

Minor performance measure	Inspection time of Barrett's esophagus
Description	Percentage of routine Barrett's surveillance endoscopies with at least one minute of inspection time per cm of circumferential Barrett's epithelium
Domain	Identification of pathology
Category	Process
Rationale	Better detection of Barrett's neoplasia
Construct	Record inspection time of the esophagus Record the Prague classification Calculate the inspection time expressed as minutes/circumferential extent of Barrett's epithelium in cm <b>Denominator:</b> Barrett's surveillance endoscopies <b>Numerator:</b> procedures in the denominator with an inspection time of >1 minute per cm of circumferential Barrett's epithelium <b>Exclusions:</b> - Presence of severe esophagitis defined as a Los Angeles classification of grade C or higher - Therapeutic procedures for treatment of Barrett's esophagus Calculation: proportion (%) Level of analysis: service and, if necessary, individual level Frequency: yearly for a sample of 100 consecutive UGI endoscopies. If the minimum standard is not reached, analysis on an individual level should be performed
Standards	Minimum standard: 90% Target standard: 90% Recording of the diagnosis of an examination (Barrett's esophagus) and the extent of the Barrett's epithelium (Prague classification) are fundamental to allow the calculation of this performance measure. On a service level this is a prerequisite that, if not possible, may hamper implementation in the short term If on a service level this performance measure is not met, measures should be taken to implement software that will allow the performance measure to be audited If the threshold is not reached for an individual endoscopist, feedback should be provided, followed by close monitoring for the next 30 procedures or a period of six months to assess the performance of the individual endoscopist
Consensus agreement for performance measure	91%
PICO number (see Appendix 2)	14
Evidence grading	Very low quality evidence

assume that a lengthier inspection of Barrett's esophagus may result in better lesion detection.

The optimal inspection time also includes rinsing the esophagus sufficiently to improve visualization, proper sedation and patient tolerance, and the use of high definition endoscopy (i.e. high definition endoscopes connected to high definition monitors using a high definition signal). At this time, there are no data to support the systematic use of any advanced imaging technique, such as chromoendoscopy or electronically enhanced endoscopy,<sup>37,38</sup> but neither is there harm in applying them when available. In the recent Benign Barrett's and CAncer Taskforce (BOB CAT) consensus, it was suggested that these techniques should be used in experienced hands only.<sup>4</sup>

The implementation of this performance measure is again dependent on the availability and development of an electronic reporting system; however, once this is in place, it should be easy to comply with. One of the research priorities should be to elucidate whether there is a correlation between inspection time and increased neoplasia detection in Barrett's esophagus in a general secondary-care setting.

The acceptance of this performance measure (Box 7) is based on agreement with the following statement:

- Accurate use of chromoendoscopy in patients with a history of ENT or lung tumors who are treated with curative intent results in a higher diagnostic yield for

**Box 7.** Use of Lugol chromoendoscopy in patients with an increased risk of SCC.

Minor performance measure	Use of Lugol chromoendoscopy in patients with an increased risk of SCC
Description	Percentage of procedures with accurate application of chromoendoscopy in patients referred for screening for SCC after curative treatment of ear, nose, and throat (ENT) or lung cancers
Domain	Identification of pathology
Category	Process
Rationale	Better detection of early esophageal SCC in patients with an increased risk
Construct	Record the use of Lugol chromoendoscopy in patients with a history of ENT or lung cancer treated with a curative intent <b>Denominator:</b> all endoscopies performed for screening for a second primary tumor after curative treatment of ENT or lung cancer <b>Numerator:</b> procedures in the denominator where Lugol chromoendoscopy is used <b>Exclusions:</b> - Allergy to iodine - Patients treated without curative intent - Patients older than 80 years - Patients with a life expectancy of less than two years Calculation: proportion (%) Level of analysis: service Frequency: every two years for a sample of all or 100 eligible UGI endoscopies, whichever is the larger
Standards	Minimum standard: 90% Target standard: 90% Because this is a relatively rare indication that may be disseminated among the endoscopists within a service, as a first step, feedback on a service can be provided. If the threshold is not met, endoscopists need to be educated about the risk in these patients and the additional value of Lugol staining for the detection of early lesions
Consensus agreement for performance measure	82%
PICO number (see Appendix 2)	15
Evidence grading	Moderate quality

the detection of squamous dysplasia and SCC. (N5.1) Agreement: 80%.

Eight studies addressed this clinical question specifically in patients with a history of head and neck tumors by comparing conventional white-light endoscopy with Lugol chromoendoscopy.<sup>39–46</sup> Because this is a screening examination by a minimally invasive technique, from a clinical point of view it only makes sense to perform it in patients who have been previously treated with curative intent for their primary tumor. For the diagnosis of SCC, five of the studies showed improvements in the rates of diagnosis, mostly for early cancers, ranging from 20–100% of detected lesions,<sup>39,41,42,45,46</sup> while all eight studies showed increased yield for dysplasia ranging from 33–100% of lesions. The overall incidence rates of lesions in this particular high risk group of patients were 2–9% for dysplasia and 1–5% for cancer after Lugol chromoendoscopy.

The usual technique in UGI endoscopy uses esophageal staining with 10–20 ml of a 2% Lugol dye solution

applied by a spray catheter or directly by the biopsy channel of the endoscope, with the esophageal examination being repeated two minutes later. In view of the fact that Lugol chromoendoscopy is a cheap and relatively easily applied technique, for which the available evidence is of moderate quality, the working group reached a high degree of agreement on the acceptance of this performance measure.

#### *Domain: management of pathology*

The acceptance of this performance measure (Box 8) is based on agreement with the following statement:

- In patients undergoing routine surveillance for non-dysplastic Barrett's esophagus, biopsies should be taken according to the Seattle protocol. (N4.6) Agreement: 100%.

The Seattle protocol typically consists of targeted biopsies of any visible lesion, followed by four

**Box 8.** Use of the Seattle protocol in Barrett's surveillance.

Key performance measure	Use of the Seattle protocol in Barrett's surveillance
Description	Percentage of patients undergoing routine Barrett's surveillance with proper application of the Seattle protocol
Domain	Management of pathology
Category	Process
Rationale	Accurate surveillance with optimal detection of Barrett's neoplasia Allowing an interval between surveillance endoscopies that is according to the guidelines
Construct	Record the Prague classification Record the use of the Seattle protocol with four biopsies taken every 2 cm along the circumferential extent of the Barrett's epithelium. Biopsies should be collected in separate jars for targeted biopsies and per level for random biopsies For example, in a C4M5 Barrett's segment, at least 12 biopsies should be taken, i.e. four at levels 0, 2, and 4 cm, and these should be put into three different jars numbered according to the biopsy location <b>Denominator:</b> all Barrett's surveillance endoscopies <b>Numerator:</b> procedures in the denominator where biopsies were taken in complete accordance with the extensive Seattle protocol, as described above <b>Exclusions:</b> <ul style="list-style-type: none"> <li>- Presence of severe esophagitis defined as Los Angeles classification of grade C or higher</li> <li>- Therapeutic procedures for treatment of Barrett's esophagus</li> <li>- Work-up endoscopy for known Barrett's neoplasia when a visible lesion is present that is defined as a type Ila, Ilc, Is, or a more advanced lesion according to the Paris classification</li> <li>- Patients with contraindications for biopsies, such as coagulopathy or the use of anticoagulants</li> </ul> Calculation: proportion (%) Level of analysis: service and, if necessary, individual level Frequency: yearly for a sample of 100 consecutive UGI endoscopies. If the minimum standard is not reached, analysis on an individual level should be performed
Standards	Minimum standard: 90% Target standard: 90% Recording of the diagnosis of Barrett's esophagus and the Prague classification are fundamental to allow the calculation of this performance measure. In addition, a link with a pathology database would be ideal to allow automatic audit If the threshold is not reached on a service level, the availability of registration of the parameters should first be facilitated; if this is available, awareness of the need for registration should be increased If the threshold is not reached for an individual endoscopist, feedback should be provided, followed by a close monitoring for the next 30 procedures or a period of six months to assess the performance of the individual endoscopist
Consensus agreement for performance measure	100%
PICO numbers (see Appendix 2)	16-18
Evidence grading	Very low quality of evidence

quadrant biopsies taken every 2 cm along the extent of the circumference of the Barrett's esophagus<sup>47</sup> all collected in different containers per level and per lesion. This is generally accepted in guidelines to be the standard method for Barrett's esophagus surveillance.<sup>37,38,48</sup>

The acceptance of this protocol dates back to several observational – sometimes contradictory – studies, which were mainly performed in an era prior to advanced imaging, that suggested better detection of

neoplasia and possibly a reduction in mortality. In a retrospective cohort study including 362 patients with  $\geq 3$  cm Barrett's esophagus undergoing endoscopic surveillance, 180 patients received a systematic Seattle biopsy protocol and 182 subjects received a non-systematic biopsy strategy.<sup>49</sup> The Seattle protocol detected significantly more low grade dysplasia (LGD; 18.9% vs 1.6%;  $p < 0.001$ ) and HGD (2.8% vs 0%;  $p = 0.03$ ). In the non-Seattle biopsy group, three patients died of

invasive Barrett's esophagus adenocarcinoma, compared with none in the Seattle group. In concordance with this study, Peters et al.<sup>50</sup> reported a cohort of patients treated endoscopically for early Barrett's esophagus neoplasia and found that those without a prior diagnosis of dysplasia were more likely not to have undergone the Seattle biopsy protocol.

In the era prior to an established endoscopic treatment of early Barrett's esophagus neoplasia particularly, controversy existed as to whether an intensified protocol better predicted the presence of cancer in comparison to a less intensive protocol. Reid et al.<sup>47</sup> intensified the classical protocol to four quadrant biopsies every 1 cm for patients followed up after a diagnosis of HGD and suggested that a 2 cm biopsy protocol would miss 50% of the cancers. In contrast, Kariv et al.<sup>51</sup> found that a 2 cm interval for the biopsy protocol was sufficient to detect cancer prior to esophagectomy. Studies using advanced imaging techniques in experienced referral centers suggest that in the future there may be a role for new techniques to replace the Seattle protocol, but currently there are insufficient data to support this.<sup>38</sup>

Because of the widespread acceptance of this protocol in all guidelines, the working group agreed fully that, despite the low quality evidence, adherence to the Seattle protocol could serve as a valuable performance measure to monitor UGI endoscopy practice. It is important to emphasize that this parameter is only applicable in the surveillance setting.

From a practical viewpoint, containers should be labeled according to the level at which the biopsy was taken. The working group suggests a coding system that unequivocally allows a location to be allocated to each container using a two number combination "xxyy." In this "xx" refers to the distance from the incisors and "yy" to the location on a clock with the three o'clock position corresponding to the lesser curvature (scope in neutral position) and with 00 indicating random biopsies. For instance, 4000 would indicate random biopsies taken at 40 cm from the incisors, while 3805 stands for a targeted biopsy taken from a lesion at 38 cm from the incisors and in the five o'clock position.

The acceptance of this performance measure (Box 9) is based on agreement with the following statements:

- For the diagnosis of intestinal metaplasia and *Helicobacter pylori*, at least two biopsies of the antrum and two biopsies of the corpus should be taken. (N6.2) Agreement: 80%.
- In addition to two biopsies of the antrum and two biopsies of the corpus, a biopsy in the incisura is demanded for both the Operative Link for Gastritis Assessment (OLGA) and Operative Link

on Gastric Intestinal Metaplasia (OLGIM) classifications. (N6.3) Agreement: 80%.

The MAPS guideline recommends that for the assessment of extension of gastric atrophy and intestinal metaplasia, beyond performing the best available endoscopy in terms of technology and the time for inspection, at least two biopsies must be taken from the antrum and two from the body of the stomach, and these must be placed into separate containers.<sup>20</sup> This recommendation is in concordance with the minimum standards for pathology as described in the OLGA or OLGIM grading systems for gastritis.<sup>52,53</sup> These grading systems require an additional separate biopsy from the incisura. However, several studies have addressed the issue of the number of biopsies and inconsistency exists regarding the incisura biopsy in terms of increased diagnostic yield.<sup>54-59</sup>

De Vries et al.,<sup>54</sup> in a prospective cohort study comparing different numbers of non-targeted biopsies (five, seven, or nine) to the 12-biopsy scheme (used as the reference), found that, in a population with a low gastric cancer risk, at least nine non-targeted biopsies should be taken from the cardia, lesser curvature of the corpus, angulus, and antrum to achieve the best diagnostic yield. Guarner et al.<sup>55</sup> compared protocols of three, five, and seven biopsies and found that the five-biopsy protocol reached 100% sensitivity for *H. pylori*, 96% for atrophy, and 95% for metaplasia and dysplasia.

Eriksson et al.,<sup>56</sup> in consecutive patients from a similar low risk population, took six biopsies (two from the antrum, two from incisura, and two from corpus). While no patients showed dysplasia in their incisura biopsies, these biopsies were the only ones to show intestinal metaplasia but, as this was seen in 3.3% of cases only, they concluded that routine biopsy of the incisura would provide little additional information. El-Zimaity et al.<sup>57</sup> also found that intestinal metaplasia was missed in more than 50% of cases, and that this was independent of the site of biopsy and that no set or site of biopsy specimens, including the incisura, could reliably exclude the presence of intestinal metaplasia.

On the other hand, Isajevs et al.<sup>58</sup> assessed the relevance of the incisura biopsy and concluded that, if the incisura biopsy was excluded, down-staging would occur in 18% of cases for the OLGA classification and 4% for the OLGIM, resulting in a 30-35% down-grading from high risk to low risk in terms of the OLGA/OLGIM stages. Finally, Stolte et al.,<sup>59</sup> using the same five-biopsy protocol, concluded that the presence of antral mucosa at the incisura was associated with considerably more severe gastritis (14% atrophy and 20% intestinal metaplasia in the antrum) than the

**Box 9.** Identification of patients at risk for gastric cancer.

Minor performance measure	Identification of patients at risk for gastric cancer
Description	Percentage of patients in which MAPS guidelines are followed when applicable
Domain	Management of pathology
Category	Process
Rationale	Accurate application of the MAPS guidelines identifies patients at risk for gastric cancer Adequate surveillance allows the detection of gastric cancer at an early stage
Construct	Record the procedures in which gastritis is detected, and where screening for HP gastritis and intestinal metaplasia are performed Record if at least two biopsies from the antrum and two biopsies from the corpus were taken and placed into two different jars for histology (MAPS guidelines) <b>Denominator:</b> all endoscopic examinations where assessment of the gastric cancer risk is considered clinically relevant (see exclusion criteria) <b>Numerator:</b> procedures in the denominator in which at least two biopsies from the antrum and two biopsies from the corpus were taken and placed into two different jars <b>Exclusions:</b> - Therapeutic procedures - UGI with normal gastric findings - Gastric findings that do not need the application of guidelines - Follow-up of intestinal metaplasia - Work-up endoscopy for known gastric dysplasia Calculation: proportion (%) Level of analysis: service Frequency: every two years for a sample of 100 eligible UGI endoscopies
Standards	Minimum standard: 90% Target standard: 90% Recording the diagnosis of an examination is fundamental to allow further assessment of the gastric cancer risk and calculation of this performance measure. Implementation may therefore be difficult and depend largely on the availability of applicable software on a service level If the threshold is not reached on a service level, the availability of registration for the parameters should be facilitated. If this is in place, awareness of the need to follow the MAPS guidelines should be raised
Consensus agreement for performance measure	91%
PICO number (see Appendix 2)	19
Evidence grading	Very low quality of evidence

presence of corpus mucosa at the incisura (only 2% atrophy and 6% intestinal metaplasia).

From a practical and clinical point of view, five non-targeted biopsies overall, comprising two from the antrum, one from the incisura, and two from the corpus, seems to provide the most relevant information without compromising clinical applicability.

We do realize that the MAPS guidelines address more than just taking biopsies to assess the extent of atrophy or metaplasia. However, the emphasis of this performance measure lies in identifying patients at risk that should be followed up. It is obvious that the MAPS guidelines remain applicable independent of the proposed performance measures. Furthermore, depending on the prevalence of a certain disease, the

attention that is given to the corresponding performance measure may vary geographically throughout Europe. For instance, follow-up and adequate diagnosis of Barrett's esophagus will be more important in Western Europe, whereas intestinal metaplasia of the stomach may carry a higher interest in Eastern and Southern Europe.

**Domain: complications**

The acceptance of this performance measure (Box 10) is based on agreement with the following statements:

- The perforation rate following polypectomy or endoscopic mucosal resection (EMR) in the

**Box 10.** Monitoring complications after therapeutic endoscopy.

Key performance measure	Monitoring complications after therapeutic endoscopy
Description	Percentage of patients monitored for complications (adverse events) after therapeutic UGI endoscopy
Domain	Complications
Category	Outcome/process
Rationale	Monitoring of the incidence of complications after therapeutic endoscopy is important to assess the safety of procedures, to identify possible targets for improvement, and to allow patients to be accurately consented for procedures
Construct	<p>Record therapeutic procedures including:</p> <ul style="list-style-type: none"> <li>- Savary dilation</li> <li>- Pneumatic dilation</li> <li>- Endoscopic resection of lesions in the esophagus, stomach, and duodenum</li> <li>- Percutaneous endoscopic gastrostomy (PEG) insertions</li> <li>- Stent placement</li> <li>- Varices band ligation</li> <li>- Endoscopic hemostasis</li> <li>- Endoscopic ablation (Barrett's epithelium; gastric antral vascular ectasia (GAVE); squamous epithelium, duodenal mucosa)</li> </ul> <p>Record the following parameters:</p> <ul style="list-style-type: none"> <li>- Immediate complications</li> <li>- Delayed complications: record if patient was contacted between seven and 14 days after the procedure to assess post-procedural complications ideally the patient should have been notified beforehand that this contact would be made</li> </ul> <p><b>Denominator:</b> all applicable therapeutic procedures  <b>Numerator:</b> number of applicable therapeutic procedures with accurate registration of complications  <b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>- Emergency procedures</li> <li>- Patients who refuse to be contacted</li> </ul> <p>Calculation: proportion (%)  Level of analysis: service  Frequency: yearly on an audit sample of 100 random eligible endoscopy reports</p>
Standards	<p>Minimum standard: 95%  Target standard: 95%</p> <p>Implementation of these performance measures is mainly situated on a service level. Because of the lack of standardized grading of complications into major or minor, a description of the action related to the complication should be given (e.g. need for transfusion or hospitalization, prolonged hospitalization, surgery, death, need for dilation, need for endoscopic re-intervention), along with the time from the endoscopic procedure to onset of the complication</p> <p>Recording of the type of therapeutic procedure should be detailed enough to allow subgroup analysis</p> <p>Endoscopic reporting systems should allow the reporting of complications, including the absence of immediate complications, and the type of complication (hemorrhage, perforation, or anesthesia-related)</p> <p>Ideally the 30-day complication rate should also be calculated but this can be implemented at a later stage once a system to record complications systematically is in place</p>
Consensus agreement for performance measure	91%
PICO numbers (see Appendix 2)	20-25
Evidence grading	Very low quality of evidence

- esophagus, stomach, or duodenum should not exceed 2%. (N9.1) Agreement: 54%.
- The rate of clinically significant bleeding following polypectomy or EMR in the esophagus, stomach, or duodenum should not exceed 10%. (N9.2) Agreement: 64%.
  - The perforation rate following pneumatic or Savary dilation in the esophagus should not exceed 1%. (N9.3) Agreement: 73%.

For this domain, we specifically addressed adverse events and harms for procedures that are generally and frequently carried out in all endoscopic units. We focused on the perforation and bleeding rate after Savary or pneumatic dilation and endoscopic resections in the UGI tract.

A total of 37 studies were included for complications after dilation.<sup>60–87</sup> They generally seemed to have prospectively recruited patients, but the information was often not very clear. Overall 3263 patients were included, of which 2202 were adults and 1061 children. Overall 8524 Savary and 5491 balloon dilations were performed. None of the studies reported cases of serious bleeding, but the majority of the studies did not assess this outcome. Perforations occurred in 0.98% of cases of balloon dilation and in 0.68% of cases of Savary dilation. Similarly, for adverse events after endoscopic resection, 38 papers were included.<sup>88–118</sup> The perforation rates were 1.6%, 0.98%, and 1.61% in the esophagus, stomach, and duodenum, respectively, with bleeding rates of 4%, 6.9%, and 9.2%, respectively.

Although the literature search yielded the highest number of included papers for these PICO, including several systematic reviews, the working group could not agree on a predefined maximal allowance for these post-procedural adverse events. This was attributed to the fact that the overall quality of the evidence was graded as very low, being retrospective in nature and with it not always being clear if patients had been consecutively included in the studies. For these indications, the data were therefore not sufficiently adequate to decide on a threshold that would be used to audit an endoscopy service. Indeed, the final result would to a large extent be determined by the denominator, and it is therefore not clear what the incidence of adverse events would be in individual centers with lower numbers.

The working group did however reach agreement on the fact that patients should be monitored for adverse events or harms after therapeutic interventions. This monitoring will generate more realistic numbers,

which in turn can be used to determine a minimum number of procedures per service or operator for these interventions (see below).

### Domain: procedure numbers

In the absence of any evidence regarding the number of procedures needed for an individual to be certified to perform UGI endoscopy, we were not able to set any minimum numbers (Box 11).

Any recommendation in terms of the minimum annual number of procedures per endoscopist that are required to maintain adequate levels of quality would need to be based on an established strong association of poor quality with a minimum threshold number of procedures performed per year; however, such data are unavailable. The working group anticipates that, with application of the present performance measures, information will come to light to clarify whether such a concept does apply to diagnostic and/or therapeutic UGI endoscopy.

### Domain: patient experience

Patient experience and satisfaction are important outcome measures of endoscopy in general. The UGI working group concluded that this should be measured after any endoscopic procedure. In general, there is lack of evidence assessing the effect of certain logistic or procedural aspects on patient's satisfaction and experience (Box 12).

The working group members concluded that this is a domain for research and, because it applies to all forms of endoscopy within an endoscopy service, it was suggested that this particular domain resides more under the service working group. Undoubtedly, several measures can be undertaken to improve patient's experience. For instance, providing an information brochure on UGI endoscopy at least one day prior to the procedure has been shown to result in less anxiety beforehand and greater satisfaction after the procedure.<sup>119</sup>

### Domain: post-procedure

The acceptance of this performance measure (Box 13) is based on agreement with the following statements:

- In a Barrett's surveillance program, the incidence of dysplasia should be monitored. (N4.7) Agreement: 80%.

#### Box 11. Procedure numbers.

Performance measure	No current standard defined
---------------------	-----------------------------

#### Box 12. Patient experience.

Performance measure	No current standard defined
---------------------	-----------------------------

**Box 13.** Barrett's patient registry.

Minor performance measure	Barrett's patient registry
Description	Percentage of patients with a confirmed diagnosis of Barrett's esophagus that are entered into a registry to monitor the incidence of dysplasia
Domain	Post-procedure
Category	Process/structural
Rationale	Better follow-up of Barrett's patients helps to identify risk factors, and helps with an accurate incidence of neoplasia and adherence to surveillance guidelines
Construct	Record all patients with a diagnosis of Barrett's esophagus Cross-match with registration in a Barrett's registry <b>Denominator:</b> all patients with a diagnosis of Barrett's esophagus of at least 1 cm circumferential extent and histologically confirmed specialized intestinal metaplasia <b>Numerator:</b> patients in the denominator who are registered in a Barrett's surveillance database <b>Exclusions:</b> - Absence of intestinal metaplasia in the biopsies - All patients with suspected Barrett's esophagus that is less than C1M1 according to the Prague classification - Patients older than 75 years - Patient's with contraindications for biopsies Calculation: Proportion (%) Level of analysis: Service Frequency: every two years for a sample of 100 eligible/applicable UGI endoscopies
Standards	Minimum standard: 85% Target standard: 85% Implementation of the measurement of this performance measure on a service level is challenging. Implementation of performance measures 5, 6, and 8 is a prerequisite. Therefore this is a regarded as a minor performance measure, mainly focusing on the real incidence and prevalence of the disease as an important research question
Consensus agreement for performance measure	82%
PICO (see Appendix 2)	26
Evidence grading	Very low quality of evidence

- The incidence of HGD in a Barrett's surveillance program, when diagnosed by at least two specialist gastrointestinal pathologists, should not be lower than 0.1% per year. (N4.8) Agreement: 70%.

As with the colonic adenoma detection rate that is used as a performance measure for colonoscopy, it would seem appropriate for UGI endoscopy to use a minimum detection rate for dysplasia in the surveillance of Barrett's esophagus. From the PICO search, 28 studies with 49,815 patients were finally included.<sup>49,120–146</sup> All of the studies included patients with a diagnosis of Barrett's esophagus who underwent regular surveillance. Of the 28 studies, 17 were retrospective or prospective studies assessing prevalence of LGD and HGD at baseline and the incidence of LGD and HGD during follow-up. The length of follow-up ranged from 1.6–6 years, with a median of four years. The remaining studies were cross-

sectional studies that reported prevalence data, although often they had objectives other than the assessment of prevalence. These cross-sectional studies had, on average, smaller samples sizes ranging from 30–295 patients, with a median of 80 patients included. Sample sizes of the cohort studies ranged from 121–42,207 included patients, with a median of 277 patients.

Although the quality of the evidence was rated as moderate, because of inconsistency in the data, no agreement was achieved in the Delphi process on a specific cut-off for the detection of dysplasia. Indeed, the prevalence of LGD ranged from 0.6–33.3% in the cross-sectional studies and from 0–37.2% in the cohort studies, with the prevalence of HGD ranging from 0–14.6% and 0–23.9%, respectively. The incidence of LGD and HGD ranged from 2–34.5% and from 0–5.8%, with median values of 14.7% and 2%, respectively.

Although no agreement was obtained on the cut-off for dysplasia detection, the working group members agreed on the fact that the incidence of dysplasia in a Barrett's esophagus surveillance program should be monitored in order to obtain more consistent and accurate epidemiological data. When these data become available, a more realistic cut-off value may be determined, taking into account geographical differences and other risk factors of progression.

### General conclusions, research priorities, and future prospects

This paper describes the first performance measures generated by evidence-based consensus that can be used for UGI endoscopy. We used a systematic and scientifically sound methodology to substantiate the proposed measures with available evidence where possible. As this is a largely unexplored field, most of the generated evidence is, as expected, graded as low quality. This in itself generates an important research priority, which is merely to measure the proposed performance measures and to evaluate whether they do in fact influence health outcome.

The working group identified several additional research priorities. These are listed in Table 2 and will be addressed in an additional manuscript from the ESGE research committee.

The first step now is to implement these new performance measures into endoscopy practice over Europe. This is the only way forward that can evaluate the actual value of the performance measures and allow their adaptation in future. The working group members emphasize that all performance measures were perceived as important but, in order to facilitate their implementation, we made a distinction between key performance measures and minor performance measures. Although this distinction is somewhat arbitrary, attention was paid especially to patient safety, patient service (increasing diagnostic yield), and the feasibility of implementation. Indeed, some of the performance measures may be more difficult than others to implement or, because of geographical differences in disease prevalence, may be less relevant in certain centers.

The implementation of performance measures is important to identify services and individual endoscopists with lower levels of performance. We encourage individual endoscopists, as well as heads of endoscopy units, to start the implementation of these performance measures without delay. At a unit level, this may well mean investing in hardware to accommodate a more efficient auditing process.

Through individual feedback, measures can be taken to improve quality to rise above the proposed minimum

thresholds. This should not be regarded as a “big brother” strategy with the goal of penalizing specific endoscopists, but rather as a tool to improve the quality of endoscopy in general, improve patient outcomes, and provide training and assistance where needed.

A second barrier may be the financial repercussions of implementing a quality control system. We want to encourage hospital management to support the implementation of these performance measures in their endoscopy services. We think that in an era where general hospital accreditation is becoming more and more important, hospital administrations will be more inclined to support such actions. Moreover, we owe it to our patients to overcome individual or financial barriers to ensure that endoscopy services are of the highest quality and to set research priorities to gather data that will inform the next generation of performance measures.

### Supplementary Material

The evolution and adaptation of the different PICO and clinical statements during the Delphi voting process can be viewed in Supplementary Material.

### Declaration of conflicting interests

R Bisschops has received: consultancy fees from Boston Scientific (2015); speaker's fees from Covidien (2009–2016) and Norgine (2015); speaker's fee and hands-on training sponsorship from Olympus Europe (2013–2014); consultancy fees, speaker's fee, and research support from Pentax Europe (2008–2016) and Fujifilm (2013–2016); research support from Cook Medical (2015–2016); hands-on training sponsorship from Erbe (2013–2015); and an editorial fee from Thieme Verlag as coeditor of *Endoscopy*. E Coron has received consultancy fees from Mauna Kea Technologies (2011–2015) and Covidien (2015–2016); speaker's fees from Olympus and Cook Medical; and receives research support from Fujifilm and Mauna Kea Technologies. O Pech has received speaker's fees from Medtronic, Boston Scientific, Olympus, Fujifilm, and Norgine. K Ragunath has received educational grants, speaker honorarium, and consultancy fees from Olympus; educational grants and research support from COOK; educational grants and research support from Covidien; consultancy fees and research support from Boston Scientific; research support from Astra Zeneca; research support from Pentax. B Weusten has received financial support for institutional review board (IRB)-approved studies from GI Solutions and Covidien, ERBE, and C2Therapeutics. R Valori is a director of Quality Solutions for Healthcare, a company providing consultancy for improving quality in healthcare, and of AnderVal Ltd, a company providing endoscopy skills training. C Spada has received training support from Given Imaging (2013 and 2014). M Bretthauer receives funds from Thieme Verlag for editorial work for *Endoscopy*. C Bennett owns and works for Systematic Research Ltd; and received a consultancy fee from ESGE to provide scientific, technical, and methodological expertise

for the present project. C Senore's department receives PillCam Colon devices from Covidien-Given to conduct studies, and loaner Fuse systems from EndoChoice. M Dinis-Ribeiro receives funds from Thieme Verlag for editorial work for *Endoscopy*; his department has received support from Olympus for a teaching protocol (from August 2014 to July 2015). MD Rutter's department receives research funding from Olympus for a colitis surveillance trial (2014 to present). M Areia, D Dobru, B Kaskas, R Kuvaev, P Familiari, D Domagk and MF Kaminski have no competing interests.

### Funding

The authors gratefully acknowledge the contributions from: Stuart Gittens, ECD Solutions in the development and running of the web platform; Iwona Escreet and all at Hamilton Services for project administrative support; The Scottish Intercollegiate Guidelines Network for hosting the critical appraisal module; and The Research Foundation-Flanders (FWO) for providing funding for Raf Bisschops. UEG supplied cofunding and additional project governance to this endeavor.

### References

- Rutter MD, Senore C, Bisschops R, et al. The European Society of Gastrointestinal Endoscopy quality improvement initiative: Developing performance measures. *Endoscopy* 2016; 48: 81–89.
- Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. *NEJM* 2010; 362: 1795–1803.
- Barclay RL, Vicari JJ, Doughty AS, et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. *NEJM* 2006; 355: 2533–2541.
- Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: A large-scale review and Delphi consensus for management of Barrett's esophagus with no dysplasia, indefinite for, or low-grade dysplasia. *Am J Gastroenterol* 2015; 110: 662–682; quiz 683.
- Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. *Gastroenterology* 2012; 143: 336–346.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. *Br Med J* 2008; 336: 924–926.
- Koeppe A, Lubini M, Bonadeo N, et al. Comfort, safety and quality of upper gastrointestinal endoscopy after 2 hours fasting: A randomized controlled trial. *BMC Gastroenterol* 2013; 13: 158.
- De Silva AP, Amarasiri L, Liyanage MN, et al. One-hour fast for water and six-hour fast for solids prior to endoscopy provides good endoscopic vision and results in minimum patient discomfort. *J Gastroenterol Hepatol* 2009; 24: 1095–1097.
- Teh JL, Tan JR, Lau LJF, et al. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. *Clin Gastroenterol Hepatol* 2015; 13: 480–487; e2.
- Gupta N, Gaddam S, Wani SB, et al. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus. *Gastrointest Endosc* 2012; 76: 531–538.
- Park CH, Kim B, Chung H, et al. Endoscopic quality indicators for esophagogastroduodenoscopy in gastric cancer screening. *Dig Dis Sci* 2015; 60: 38–46.
- Rey JF and Lambert R. ESGE recommendations for quality control in gastrointestinal endoscopy: Guidelines for image documentation in upper and lower GI endoscopy. *Endoscopy* 2001; 33: 901–903.
- Yao K. The endoscopic diagnosis of early gastric cancer. *Ann Gastroenterol Q Publ Hell Soc Gastroenterol* 2013; 26: 11–22.
- Bretthauer M, Aabakken L, Dekker E, et al. Requirements and standards facilitating quality improvement for reporting systems in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) position statement. *Endoscopy* 2016; 48: 291–294.
- Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: A progress report on observer agreement. *Gastroenterology* 1996; 111: 85–92.
- Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. *Gut* 1999; 45: 172–180.
- Armstrong D. Review article: Towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia. *Aliment Pharmacol Ther* 2004; 20: S40–S47; discussion S61–S62.
- Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: The Prague C & M criteria. *Gastroenterology* 2006; 131: 1392–1399.
- Barclay RL, Vicari JJ and Greenlaw RL. Effect of a time-dependent colonoscopic withdrawal protocol on adenoma detection during screening colonoscopy. *Clin Gastroenterol Hepatol* 2008; 6: 1091–1098.
- Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa. *Endoscopy* 2012; 44: 74–94.
- Areia M, Dinis-Ribeiro M and Rocha Gonçalves F. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. *Helicobacter* 2014; 19: 425–436.
- Lambert R and Lightdale CJ. The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach, and colon – November 30 to December 1, 2002. *Gastrointest Endosc* 2003; 58: S3–S4.
- Axon A, Diebold MD, Fujino M, et al. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. *Endoscopy* 2005; 37: 570–578.
- Van Doorn SC, Hazewinkel Y, East JE, et al. Polyp morphology: An interobserver evaluation for the Paris classification among international experts. *Am J Gastroenterol* 2015; 110: 180–187.

25. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: A progress report on observer agreement. *Gastroenterology* 1996; 111: 85–92.
26. Pandolfino JE, Vakil NB and Kahrilas PJ. Comparison of inter- and intraobserver consistency for grading of esophagitis by expert and trainee endoscopists. *Gastrointest Endosc* 2002; 56: 639–643.
27. Vahabzadeh B, Seetharam AB, Cook MB, et al. Validation of the Prague C & M criteria for the endoscopic grading of Barrett's esophagus by gastroenterology trainees: A multicenter study. *Gastrointest Endosc* 2012; 75: 236–241.
28. Alvarez Herrero L, Curvers WL, van Vilsteren FGI, et al. Validation of the Prague C&M classification of Barrett's esophagus in clinical practice. *Endoscopy* 2013; 45: 876–882.
29. Forrest JA, Finlayson ND and Shearman DJ. Endoscopy in gastrointestinal bleeding. *Lancet* 1974; 2: 394–397.
30. De Groot NL, Van Oijen MGH, Kessels K, et al. Reassessment of the predictive value of the Forrest classification for peptic ulcer rebleeding and mortality: Can classification be simplified? *Endoscopy* 2014; 46: 46–52.
31. Gralnek I, Dumonceau J-M, Kuipers E, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2015; 47: a1–a46.
32. Cheng H-T, Cheng C-L, Lin C-H, et al. Caustic ingestion in adults: The role of endoscopic classification in predicting outcome. *BMC Gastroenterol* 2008; 8: 31.
33. LaBrecque D, Khan AG, Sarin SK, et al. *Esophageal varices. World Gastroenterology Organisation global guidelines*, <http://www.worldgastroenterology.org/UserFiles/file/guidelines/esophageal-varices-english-2014.pdf> (2014, accessed 4 July 2016).
34. De Franchis R and Baveno V faculty. Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J Hepatol* 2010; 53: 762–768.
35. Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. *Lancet* 1989; 2: 783–785.
36. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol* 2015; 110: 223–262; quiz 263.
37. Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: A large-scale review and Delphi consensus for management of Barrett's esophagus with no dysplasia, indefinite for, or low-grade dysplasia. *Am J Gastroenterol* 2015; 110: 662–682; quiz 683.
38. Fitzgerald RC, di Pietro M, Ragnanath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. *Gut* 2014; 63: 7–42.
39. Tincani AJ, Brandalise N, Altemani A, et al. Diagnosis of superficial esophageal cancer and dysplasia using endoscopic screening with a 2% lugol dye solution in patients with head and neck cancer. *Head Neck* 2000; 22: 170–174.
40. Hashimoto CL, Iriya K, Baba ER, et al. Lugol's dye spray chromoendoscopy establishes early diagnosis of esophageal cancer in patients with primary head and neck cancer. *Am J Gastroenterol* 2005; 100: 275–282.
41. Dubuc J, Legoux J-L, Winnock M, et al. Endoscopic screening for esophageal squamous-cell carcinoma in high-risk patients: A prospective study conducted in 62 French endoscopy centers. *Endoscopy* 2006; 38: 690–695.
42. Boller D, Spieler P, Schoenegg R, et al. Lugol chromoendoscopy combined with brush cytology in patients at risk for esophageal squamous cell carcinoma. *Surg Endosc* 2009; 23: 2748–2754.
43. Carvalho R, Areia M, Brito D, et al. Diagnostic accuracy of lugol chromoendoscopy in the oesophagus in patients with head and neck cancer. *Rev Esp Enferm Dig* 2013; 105: 79–83.
44. Komínek P, Vitek P, Urban O, et al. Chromoendoscopy to detect early synchronous second primary esophageal carcinoma in patients with squamous cell carcinomas of the head and neck? *Gastroenterol Res Pract* 2013; 2013: Article id: 236264. 5pp. DOI: 10.1155/2013/236264.
45. Ina H, Shibuya H, Ohashi I, et al. The frequency of a concomitant early esophageal cancer in male patients with oral and oropharyngeal cancer. *Screening results using Lugol dye endoscopy*. *Cancer* 1994; 73: 2038–2041.
46. Shiozaki H, Tahara H, Kobayashi K, et al. Endoscopic screening of early esophageal cancer with the Lugol dye method in patients with head and neck cancers. *Cancer* 1990; 66: 2068–2071.
47. Reid BJ, Blount PL, Feng Z, et al. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. *Am J Gastroenterol* 2000; 95: 3089–3096.
48. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology* 2011; 140: 1084–1091.
49. Abela JE, Going JJ, Mackenzie JF, et al. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. *Am J Gastroenterol* 2008; 103: 850–855.
50. Peters FP, Curvers WL, Rosmolen WD, et al. Surveillance history of endoscopically treated patients with early Barrett's neoplasia: Nonadherence to the Seattle biopsy protocol leads to sampling error. *Dis Esophagus* 2008; 21: 475–479.
51. Kariv R, Plesec TP, Goldblum JR, et al. The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. *Clin Gastroenterol Hepatol* 2009; 7: 653–658.
52. Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: The OLGA staging system. *Gut* 2007; 56: 631–636.
53. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. *Gastrointest Endosc* 2010; 71: 1150–1158.
54. De Vries AC, Haringsma J, de Vries RA, et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. *Helicobacter* 2010; 15: 259–264.

55. Guarner J, Herrera-Goepfert R, Mohar A, et al. Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. *Hum Pathol* 2003; 34: 28–31.
56. Eriksson NK, Färkkilä MA, Voutilainen ME, et al. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. *Endoscopy* 2005; 37: 532–536.
57. El-Zimaity HM and Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of *Helicobacter pylori* or intestinal metaplasia: Role of the Sydney System. *Hum Pathol* 1999; 30: 72–77.
58. Isajevs S, Liepniece-Karele I, Janciauskas D, et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage. *Eur J Gastroenterol Hepatol* 2014; 26: 510–513.
59. Stolte M, Müller H, Talley NJ, et al. In patients with *Helicobacter pylori* gastritis and functional dyspepsia, a biopsy from the incisura angularis provides useful diagnostic information. *Pathol Res Pract* 2006; 202: 405–413.
60. Cabrera Chamorro C, Méndez Manchola C, Molina Ramírez I, et al. [Endoscopic balloon dilatation of esophageal strictures in children]. *Cir Pediatr* 2013; 26: 106–111.
61. Caro L, Sánchez C, Rodríguez P, et al. Endoscopic balloon dilation of anastomotic strictures occurring after laparoscopic gastric bypass for morbid obesity. *Dig Dis* 2008; 26: 314–317.
62. Contini S, Garatti M, Swarray-Deen A, et al. Corrosive oesophageal strictures in children: Outcomes after timely or delayed dilatation. *Dig Liver Dis* 2009; 41: 263–268.
63. Contini S, Tesfaye M, Picone P, et al. Corrosive esophageal injuries in children. A shortlived experience in Sierra Leone. *Int J Pediatr Otorhinolaryngol* 2007; 71: 1597–1604.
64. Dellon ES, Gibbs WB, Rubinas TC, et al. Esophageal dilation in eosinophilic esophagitis: Safety and predictors of clinical response and complications. *Gastrointest Endosc* 2010; 71: 706–712.
65. Fry LC, Mönkemüller K, Neumann H, et al. Incidence, clinical management and outcomes of esophageal perforations after endoscopic dilatation. *Zeitschrift für Gastroenterol* 2007; 45: 1180–1184.
66. Hagel AF, Naegel A, Dauth W, et al. Perforation during esophageal dilatation: A 10-year experience. *J Gastrointest Liver Dis* 2013; 22: 385–389.
67. Jayakrishnan VK and Wilkinson AG. Treatment of oesophageal strictures in children: A comparison of fluoroscopically guided balloon dilatation with surgical bouginage. *Pediatr Radiol* 2001; 31: 98–101.
68. Ko H-K, Shin JH, Song H-Y, et al. Balloon dilation of anastomotic strictures secondary to surgical repair of esophageal atresia in a pediatric population: Long-term results. *J Vasc Interv Radiol* 2006; 17: 1327–1333.
69. Lain A, Cerdá J, Cañizo A, et al. [Analysis of esophageal strictures secondary to surgical correction of esophageal atresia]. *Cir Pediatr* 2007; 20: 203–208.
70. Lakhdar-Idrissi M, Khabbache K and Hida M. Esophageal endoscopic dilations. *J Pediatr Gastroenterol Nutr* 2012; 54: 744–747.
71. Lan LCL, Wong KKY, Lin SCL, et al. Endoscopic balloon dilatation of esophageal strictures in infants and children: 17 Years' experience and a literature review. *J Pediatr Surg* 2003; 38: 1712–1715.
72. Lang T, Hümmer HP and Behrens R. Balloon dilation is preferable to bouginage in children with esophageal atresia. *Endoscopy* 2001; 33: 329–335.
73. Lian JJ, Ma LL, Hu JW, et al. Endoscopic balloon dilatation for benign esophageal stricture after endoscopic submucosal dissection for early esophageal neoplasms. *J Dig Dis* 2014; 15: 224–229.
74. Na HK, Choi KD, Ahn JY, et al. Outcomes of balloon dilation for the treatment of strictures after endoscopic submucosal dissection compared with peptic strictures. *Surg Endosc* 2013; 27: 3237–3246.
75. Poddar U and Thapa BR. Benign esophageal strictures in infants and children: Results of Savary-Gilliard bougie dilation in 107 Indian children. *Gastrointest Endosc* 2001; 54: 480–484.
76. Qureshi S, Ghazanfar S, Leghari A, et al. Benign esophageal strictures: Behaviour, pattern and response to dilatation. *J Pak Med Assoc* 2010; 60: 656–660.
77. Rana SS, Bhasin DK, Chandail VS, et al. Endoscopic balloon dilatation without fluoroscopy for treating gastric outlet obstruction because of benign etiologies. *Surg Endosc* 2011; 25: 1579–1584.
78. Raymondi R, Pereira-Lima JC, Valves A, et al. Endoscopic dilation of benign esophageal strictures without fluoroscopy: Experience of 2750 procedures. *Hepatogastroenterology* 2008; 55: 1342–1348.
79. Romeo E, Foschia F, de Angelis P, et al. Endoscopic management of congenital esophageal stenosis. *J Pediatr Surg* 2011; 46: 838–841.
80. Said M, Mekki M, Golli M, et al. Balloon dilatation of anastomotic strictures secondary to surgical repair of oesophageal atresia. *Br J Radiol* 2003; 76: 26–31.
81. Shehata SMK and Enaba ME. Endoscopic dilatation for benign oesophageal strictures in infants and toddlers: Experience of an expectant protocol from North African tertiary centre. *Afr J Paediatr Surg* 2012; 9: 187–192.
82. Thyoka M, Barnacle A, Chippington S, et al. Fluoroscopic balloon dilation of esophageal atresia anastomotic strictures in children and young adults: Single-center study of 103 consecutive patients from 1999 to 2011. *Radiology* 2014; 271: 596–601.
83. Ukleja A, Shiroky J, Agarwal A, et al. Esophageal dilations in eosinophilic esophagitis: A single center experience. *World J Gastroenterol* 2014; 20: 9549–9555.
84. Uygun I, Arslan MS, Aydogdu B, et al. Fluoroscopic balloon dilatation for caustic esophageal stricture in children: An 8-year experience. *J Pediatr Surg* 2013; 48: 2230–2234.
85. Weintraub JL and Eubig J. Balloon catheter dilatation of benign esophageal strictures in children. *J Vasc Interv Radiol* 2006; 17: 831–835.
86. Yeming W, Somme S, Chenren S, et al. Balloon catheter dilatation in children with congenital and acquired esophageal anomalies. *J Pediatr Surg* 2002; 37: 398–402.

87. Yoda Y, Yano T, Kaneko K, et al. Endoscopic balloon dilatation for benign fibrotic strictures after curative nonsurgical treatment for esophageal cancer. *Surg Endosc* 2012; 26: 2877–2883.
88. Albéniz-Arbizu E, Pueyo-Royo A, Eguaras-Ros J, et al. Endoscopic mucosal resection for proximal superficial lesions: Efficacy and safety study in 59 consecutive resections. *Rev Esp Enferm Dig* 2012; 104: 458–467.
89. Alexander S, Bourke MJ, Williams SJ, et al. EMR of large, sessile, sporadic nonampullary duodenal adenomas: Technical aspects and long-term outcome (with videos). *Gastrointest Endosc* 2009; 69: 66–73.
90. Basford PJ, George R, Nixon E, et al. Endoscopic resection of sporadic duodenal adenomas: Comparison of endoscopic mucosal resection (EMR) with hybrid endoscopic submucosal dissection (ESD) techniques and the risks of late delayed bleeding. *Surg Endosc* 2014; 28: 1594–1600.
91. Binmoeller KF, Shah JN, Bhat YM, et al. “Underwater” EMR of sporadic laterally spreading nonampullary duodenal adenomas (with video). *Gastrointest Endosc* 2013; 78: 496–502.
92. Conio M, De Ceglie A, Filiberti R, et al. Cap-assisted EMR of large, sporadic, nonampullary duodenal polyps. *Gastrointest Endosc* 2012; 76: 1160–1169.
93. Conio M, Fisher DA, Blanchi S, et al. One-step circumferential endoscopic mucosal cap resection of Barrett’s esophagus with early neoplasia. *Clin Res Hepatol Gastroenterol* 2014; 38: 81–91.
94. Fanning SB, Bourke MJ, Williams SJ, et al. Giant laterally spreading tumors of the duodenum: Endoscopic resection outcomes, limitations, and caveats. *Gastrointest Endosc* 2012; 75: 805–812.
95. Huntington JT, Walker JP, Meara MP, et al. Endoscopic mucosal resection for staging and treatment of early esophageal carcinoma: A single institution experience. *Surg Endosc* 2015; 29: 2121–2125.
96. Inoue T, Uedo N, Yamashina T, et al. Delayed perforation: A hazardous complication of endoscopic resection for non-ampullary duodenal neoplasm. *Dig Endosc* 2014; 26: 220–227.
97. Kakushima N, Ono H, Takao T, et al. Method and timing of resection of superficial non-ampullary duodenal epithelial tumors. *Dig Endosc* 2014; 26: S35–S40.
98. Kim GH, Kim JI, Jeon SW, et al. Endoscopic resection for duodenal carcinoid tumors: A multicenter, retrospective study. *J Gastroenterol Hepatol* 2014; 29: 318–324.
99. Kim H-K, Chung WC, Lee B-I, et al. Efficacy and long-term outcome of endoscopic treatment of sporadic non-ampullary duodenal adenoma. *Gut Liver* 2010; 4: 373–377.
100. Konda VJA, Gonzalez Haba Ruiz M, Koons A, et al. Complete endoscopic mucosal resection is effective and durable treatment for Barrett’s-associated neoplasia. *Clin Gastroenterol Hepatol* 2014; 12: 2002–2010; e1–e2.
101. Lee KJ, Kim GH, Park DY, et al. Endoscopic resection of gastrointestinal lipomas: A single-center experience. *Surg Endosc* 2014; 28: 185–192.
102. Li N, Pasricha S, Bulsiewicz WJ, et al. Effects of preceding endoscopic mucosal resection on the efficacy and safety of radiofrequency ablation for treatment of Barrett’s esophagus: Results from the United States Radiofrequency Ablation Registry. *Dis Esophagus*. Epub ahead of print 30 June 2015. DOI: 10.1111/dote.12386.
103. Makazu M, Kato K, Takisawa H, et al. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer. *Dis Esophagus* 2014; 27: 42–49.
104. Matsumoto S and Yoshida Y. Selection of appropriate endoscopic therapies for duodenal tumors: An open-label study, single-center experience. *World J Gastroenterol* 2014; 20: 8624–8630.
105. Min B-H, Kim ER, Lee JH, et al. Management strategy for small duodenal carcinoid tumors: Does conservative management with close follow-up represent an alternative to endoscopic treatment? *Digestion* 2013; 87: 247–253.
106. Min YW, Min B-H, Kim ER, et al. Efficacy and safety of endoscopic treatment for nonampullary sporadic duodenal adenomas. *Dig Dis Sci* 2013; 58: 2926–2932.
107. Navaneethan U, Lourdasamy D, Mehta D, et al. Endoscopic resection of large sporadic non-ampullary duodenal polyps: Efficacy and long-term recurrence. *Surg Endosc* 2014; 28: 2616–2622.
108. Nonaka S, Oda I, Tada K, et al. Clinical outcome of endoscopic resection for nonampullary duodenal tumors. *Endoscopy* 2015; 47: 129–135.
109. Oka S, Tanaka S, Higashiyama M, et al. Clinical validity of the expanded criteria for endoscopic resection of undifferentiated-type early gastric cancer based on long-term outcomes. *Surg Endosc* 2014; 28: 639–647.
110. Oka S, Tanaka S, Nagata S, et al. Clinicopathologic features and endoscopic resection of early primary non-ampullary duodenal carcinoma. *J Clin Gastroenterol* 2003; 37: 381–386.
111. Park SM, Ham JH, Kim B-W, et al. Feasibility of endoscopic resection for sessile nonampullary duodenal tumors: A multicenter retrospective study. *Gastroenterol Res Pract* 2015; 2015: 692492. DOI: 10.1155/2015/692492.
112. Pimentel-Nunes P, Mourão F, Veloso N, et al. Long-term follow-up after endoscopic resection of gastric superficial neoplastic lesions in Portugal. *Endoscopy* 2014; 46: 933–940.
113. Qumseya B, David W, Woodward TA, et al. Safety of esophageal EMR in elderly patients. *Gastrointest Endosc* 2014; 80: 586–591.
114. Seo JY, Hong SJ, Han JP, et al. Usefulness and safety of endoscopic treatment for nonampullary duodenal adenoma and adenocarcinoma. *J Gastroenterol Hepatol* 2014; 29: 1692–1698.
115. Sohn JW, Jeon SW, Cho CM, et al. Endoscopic resection of duodenal neoplasms: A single-center study. *Surg Endosc* 2010; 24: 3195–3200.
116. Uygun A, Kadayifci A, Polat Z, et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. *J Surg Oncol* 2014; 109: 71–74.

117. Yamamoto Y, Yoshizawa N, Tomida H, et al. Therapeutic outcomes of endoscopic resection for superficial non-ampullary duodenal tumor. *Dig Endosc* 2014; 26: S50–S56.
118. Zhong Y-S, Shi Q, Wu H-F, et al. Endoscopic resection for the treatment of duodenal Brunner's adenomas. *J Laparoendosc Adv Surg Tech A* 2012; 22: 904–909.
119. Van Zuuren FJ, Grypdonck M, Crevits E, et al. The effect of an information brochure on patients undergoing gastrointestinal endoscopy: A randomized controlled study. *Patient Educ Couns* 2006; 64: 173–182.
120. Ajumobi A, Bahjri K, Jackson C, et al. Surveillance in Barrett's esophagus: An audit of practice. *Dig Dis Sci* 2010; 55: 1615–1621.
121. Bansal A, McGregor DH, Anand O, et al. Presence or absence of intestinal metaplasia but not its burden is associated with prevalent high-grade dysplasia and cancer in Barrett's esophagus. *Dis Esophagus* 2014; 27: 751–756.
122. Basu KK, Pick B and de Caestecker JS. Audit of a Barrett's epithelium surveillance database. *Eur J Gastroenterol Hepatol* 2004; 16: 171–175.
123. Bertani H, Frazzoni M, Dabizzi E, et al. Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. *Dig Dis Sci* 2013; 58: 188–193.
124. Canto MIF, Setrakian S, Willis J, et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. *Gastrointest Endosc* 2000; 51: 560–568.
125. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: A prospective study. *Am J Gastroenterol* 2003; 98: 1931–1939.
126. Egger K, Werner M, Meining A, et al. Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. *Gut* 2003; 52: 18–23.
127. Gladman L, Chapman W, Iqbal TH, et al. Barrett's oesophagus: An audit of surveillance over a 17-year period. *Eur J Gastroenterol Hepatol* 2006; 18: 271–276.
128. Gopal DV, Lieberman DA, Magaret N, et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): Results from a multicenter consortium. *Dig Dis Sci* 2003; 48: 1537–1541.
129. De Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett's oesophagus: A Dutch nationwide cohort study. *Gut* 2010; 59: 1030–1036.
130. Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: A prospective, international, randomised controlled trial. *Gut* 2013; 62: 15–21.
131. Hillman LC, Chiragakis L, Clarke AC, et al. Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma. *J Gastroenterol Hepatol* 2003; 18: 526–533.
132. Hurschler D, Borovicka J, Neuweiler J, et al. Increased detection rates for Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma. *Swiss Med Wkly* 2003; 133: 507–514.
133. Komanduri S, Swanson G, Keefer L, et al. Use of a new jumbo forceps improves tissue acquisition of Barrett's esophagus surveillance biopsies. *Gastrointest Endosc* 2009; 70: 1072–1078; e1.
134. Macdonald CE, Wicks AC and Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: Observational study. *Br Med J* 2000; 321: 1252–1255.
135. Murphy SJ, Dickey W, Hughes D, et al. Surveillance for Barrett's oesophagus: Results from a programme in Northern Ireland. *Eur J Gastroenterol Hepatol* 2005; 17: 1029–1035.
136. Oberg S, Wenner J, Johansson J, et al. Barrett esophagus: Risk factors for progression to dysplasia and adenocarcinoma. *Ann Surg* 2005; 242: 49–54.
137. Olithselvan A, Gorard DA and McIntyre AS. A surveillance programme for Barrett's oesophagus in a UK general hospital. *Eur J Gastroenterol Hepatol* 2007; 19: 305–309.
138. Pohl J, Pech O, May A, et al. Incidence of macroscopically occult neoplasias in Barrett's esophagus: Are random biopsies dispensable in the era of advanced endoscopic imaging? *Am J Gastroenterol* 2010; 105: 2350–2356.
139. Ramus JR, Gatenby PA, Caygill CPJ, et al. Surveillance of Barrett's columnar-lined oesophagus in the UK: Endoscopic intervals and frequency of detection of dysplasia. *Eur J Gastroenterol Hepatol* 2009; 21: 636–641.
140. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. *Ann Intern Med* 2000; 132: 612–620.
141. Ruge M, Zaninotto G, Parente P, et al. Barrett's esophagus and adenocarcinoma risk. *Ann Surg* 2012; 256: 788–795.
142. Sharma P, Weston AP, Topalovski M, et al. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. *Gut* 2003; 52: 24–27.
143. Sharma P, Bansal A, Mathur S, et al. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. *Gastrointest Endosc* 2006; 64: 167–175.
144. Terry NG, Zhu Y, Rinehart MT, et al. Detection of dysplasia in barrett's esophagus with in vivo depth-resolved nuclear morphology measurements. *Gastroenterology* 2011; 140: 42–50.
145. Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. *Clin Gastroenterol Hepatol* 2011; 9: 220–227; e1.
146. Wong T, Tian J and Nagar AB. Barrett's surveillance identifies patients with early esophageal adenocarcinoma. *Am J Med* 2010; 123: 462–427.

**Appendix 1.** Number of procedures that need to be used when auditing a performance measure to obtain an accurate estimate for performance.

Threshold	<i>P</i>	1- <i>P</i>	n	SE	Lower 95% CI	Higher 95% CI
0.85	0.85	0.15	100	0.03571	0.78	0.92
0.85	0.85	0.15	200	0.02525	0.80	0.90
<b>0.85</b>	<b>0.85</b>	<b>0.15</b>	<b>250</b>	<b>0.02258</b>	<b>0.81</b>	<b>0.89</b>
0.85	0.85	0.15	300	0.02062	0.81	0.89
0.85	0.85	0.15	400	0.01785	0.82	0.88
0.85	0.85	0.15	500	0.01597	0.82	0.88
0.85	0.85	0.15	1000	0.01129	0.83	0.87
0.90	0.9	0.1	100	0.03000	0.84	0.96
0.90	0.9	0.1	200	0.02121	0.86	0.94
0.90	0.9	0.1	250	0.01897	0.86	0.94
<b>0.90</b>	<b>0.9</b>	<b>0.1</b>	<b>300</b>	<b>0.01732</b>	<b>0.87</b>	<b>0.93</b>
0.90	0.9	0.1	400	0.01500	0.87	0.93
0.90	0.9	0.1	500	0.01342	0.87	0.93
0.90	0.9	0.1	1000	0.00949	0.88	0.92
0.95	0.95	0.05	100	0.02179	0.91	0.99
0.95	0.95	0.05	200	0.01541	0.92	0.98
0.95	0.95	0.05	250	0.01378	0.92	0.98
<b>0.95</b>	<b>0.95</b>	<b>0.05</b>	<b>300</b>	<b>0.01258</b>	<b>0.93</b>	<b>0.97</b>
0.95	0.95	0.05	400	0.01090	0.93	0.97
0.95	0.95	0.05	500	0.00975	0.93	0.97
0.95	0.95	0.05	1000	0.00689	0.94	0.96

SE, standard error. For performance measures with a threshold of 85%, the number is 250; for performance measures with a threshold of 90% or 95%, the number is 300. Furthermore, as indicated in the table, the additional benefit in terms of narrowing of the 95% confidence interval (CI) is negligible for bigger sample sizes. The most significant gain in accuracy is achieved by increasing the sample from 100 to 200.

**Appendix 2.** The list of specific population/patient; intervention/indicator; comparator/control; outcomes (PICOs) that were used for the final performance measures

Patient	Intervention	Comparison	Outcome
1 Patients undergoing UGI endoscopy	Time spent in the stomach	None	Higher overall diagnostic yield in the stomach
2 Patients undergoing UGI endoscopy	Time spent in the stomach	None	Higher overall diagnostic yield in the stomach
3 Patients undergoing UGI endoscopy	Visualizing a specific structure/disease	Not visualizing a specific structure/disease	Higher overall diagnostic yield in the stomach
4 Patients undergoing UGI endoscopy	Picture of anatomical landmarks	No picture documentation	Higher overall diagnostic yield
5 Patients undergoing UGI endoscopy	Picture of abnormal findings	No picture documentation	Higher overall diagnostic yield
6 Patients with reflux undergoing UGI endoscopy	Endoscopy report documenting Z line morphology	Endoscopy report not documenting Z line morphology	Higher diagnostic accuracy to diagnose reflux esophagitis
7 Patients with reflux undergoing UGI endoscopy	Documentation of Los Angeles classification	No documentation of Los Angeles classification	Diagnosis of erosive esophagitis
8 Patients undergoing UGI endoscopy	Standardized reporting system	No standardized reporting system	Higher overall diagnostic yield
9 Patients undergoing Barrett's surveillance endoscopy	Classification as per Prague criteria	No mention of Prague criteria	Accurate diagnosis of Barrett's
10 Patients with Barrett's and visible lesions	Reporting on visible lesions according to the Paris classification	No mention of visible lesion morphology and location	Accurate documentation of visible lesions in Barrett's/better communication among physicians
11 Patients with Barrett's and visible lesions	Reporting on visible lesions according to the Paris classification	No mention of visible lesion morphology and location	Higher diagnostic yield for Barrett's dysplasia.
12 Patients with a history of squamous cell ear, nose and throat tumors, treated with curative intent, referred for screening chromoendoscopy for squamous dysplasia or cancer with a visible lesion	Systematic use of standardized reporting of lesions found according to the Paris classification	No systematic report	Need to repeat the endoscopy for accurate diagnosis
13 Patients referred for gastroscopy	Systematic standardized reporting of visible lesions according to Paris classification	No systematic standardized reporting of visible lesions	Increased detection of intestinal metaplasia, dysplasia and gastric cancer
14 Barrett's patients undergoing surveillance endoscopy	Measuring the Barrett's inspection time	No measurement of inspection time	Increased dysplasia detection
15 Patients with a history of squamous cell ear, nose and throat tumors, treated with curative intent, referred for screening for squamous dysplasia or cancer	Screen by chromoendoscopy with Lugol	No screening with chromoendoscopy	Increased detection of squamous dysplasia and cancer in the esophagus

(continued)

## Appendix 2. Continued

	Patients	Intervention	Comparison	Outcome
16	Barrett's patients undergoing surveillance endoscopy	Systematic biopsy as per Seattle protocol	Non-systematic biopsy protocol followed	Early detection of neoplasia
17	Barrett's patients undergoing surveillance endoscopy	Systematic biopsy as per Seattle protocol	Non-systematic biopsy protocol followed	Decreased mortality from adenocarcinoma of the esophagus
18	Barrett's patients undergoing surveillance endoscopy	Systematic biopsy as per Seattle protocol	Non-systematic biopsy protocol followed	Detection of dysplasia or cancer at an early stage (could be searched as "need for esophagectomy" or treatment by "endoscopic resection" or "radiofrequency ablation")
19	Patients referred for gastroscopy	Systematic biopsies of antrum, corpus, and angulus	No systematic biopsies	Increased detection of intestinal metaplasia, dysplasia, and gastric cancer
20	Patients with a benign or malignant stricture in the esophagus (achalasia excluded)	Savary dilation	None	Percentage of patients with perforation
21	Patients with a benign or malignant stricture in the esophagus (achalasia excluded)	Savary dilation	None	Percentage of patients with bleeding
22	Patients with a benign or malignant stricture in the esophagus (achalasia excluded)	Pneumatic dilation	None	Percentage of patients with perforation
23	Patients with a benign or malignant stricture in the esophagus (achalasia excluded)	Pneumatic dilation	None	Percentage of patients with bleeding
24	Patients with a benign or malignant lesion in the esophagus, stomach, or duodenum (SCC, HGD, LGD, adenoma, papilloma, stomach cancer, adenocarcinoma)	Endoscopic resection (EMR or polypectomy in esophagus, stomach or duodenum)	None	Percentage of patients with perforation
25	Patients with a benign or malignant lesion in the esophagus, stomach, or duodenum (SCC, HGD, LGD, adenoma, papilloma, stomach cancer, adenocarcinoma)	Endoscopic resection (EMR or polypectomy in esophagus, stomach, or duodenum)	None	Percentage of patients with bleeding
26	Patients undergoing Barrett's surveillance endoscopy	UGI endoscopy with dysplasia in biopsy	UGI endoscopy without dysplasia in biopsy	Percentage of patients diagnosed with HGD

EMR: endoscopic mucosal resection; HGD: high grade dysplasia; LGD: low grade dysplasia; SCC: squamous cell cancer; UGI: upper gastrointestinal endoscopy.